Dateline City:
KENILWORTH, N.J.
Acquisition Grows Mercks Oncology Pre-Clinical Pipeline with Novel IDO1 and TDO Inhibitors
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that it has acquired IOmet, a privately-held UK-based
drug discovery company focused on the development of innovative
medicines for the treatment of cancer, with a particular emphasis on the
fields of cancer immunotherapy and cancer metabolism.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more